[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100402770":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":47,"collaborators":11,"id":49,"slug":11,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":11,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":11,"overallStatus":33,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Partial NMB","EXPERIMENTAL",null,[13],"Drug: Cisatracurium",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Cisatracurium","Cisatracurium will be infused to achieve Pocc targets after ensuring adequate sedation. Sedation will be titrated to avoid dyspnea, assessed with P0.1 targets between -1.5 and -3.5 cmH2O and Mechanical Ventilation Respiratory-Distress Observation Scale (MV-RDOS) ≤ 3. If there is no sign of dyspnea or discomfort based on P0.1, MV-RDOS, hemodynamics and the train-of-four ratio is ≥ 60% (compatible with ability to interact using peripheral muscles), sedation will be carefully reduced. After establishing a sedation and NMB strategy at which safe spontaneous breathing is achieved, we will seek to determine whether these targets can be maintained over a 48-hour period or until hypoxemia is resolved (FiO2 ≤ 40% on PEEP ≤ 8 cmH2O), whichever occurs first.",[9],[21],{"name":22,"affiliation":5,"role":23},"Ewan Goligher, MD, PhD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"Glauco M. Plens, MD, PhD","CONTACT","4373299590","glauco.plens@uhn.ca",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"University Health Network","RECRUITING","Toronto","Ontario","M5G 2N2","Canada",{"type":39,"coordinates":40},"Point",[41,42],-79.39864,43.70643,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":11,"phoneExt":11,"email":29},"Glauco Plens, MD PhD",{"type":48,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100402770",false,"NCT04524585","Partial Neuromuscular Blockade in Acute Hypoxemic Respiratory Failure","PNEUMA","Inclusion Criteria:\n\nPatients supported on invasive mechanical ventilation for moderate to severe AHRF (PaO2\u002FFiO2 \\\u003C 150 mm Hg or FiO2 ≥ 60% with an SpO2 ≤ 97% or receiving venovenous extracorporeal membrane oxygenation)\n\nExclusion Criteria:\n\n1. Contraindication to neuromuscular blockade (allergy, history of malignant hyperthermia)\n2. Contraindication to ulnar nerve stimulation (bilateral peripheral neuropathy, skin burns on both wrists)\n3. Previous history of a formally diagnosed neuromuscular disorder","ALL","18 Years",{"count":58,"type":59},23,"ESTIMATED","INTERVENTIONAL",[62],"NA","PNEUMA is a preliminary safety and feasibility trial of a novel approach to the titration of neuromuscular blockade (NMB) to safe spontaneous breathing in patients with moderate to severe acute hypoxemic respiratory failure (AHRF) supported with invasive mechanical ventilation.",[65,66,67],"Respiratory Insufficiency","Neuromuscular Blockade","Mechanical Ventilation","2025-12-30",{"date":70,"type":71},"2026-01-06","ACTUAL",{"date":73,"type":71},"2020-10-01",{"date":75,"type":59},"2027-03-01",{"name":5,"class":6},1]